TY  - JOUR
T1  - LIfe expectancy after treatment for systolic hypertension
AU  - Coca S
Y1  - 2012/04/04
N1  - 10.1001/jama.2012.389
JO  - JAMA
SP  - 1368
EP  - 1369
VL  - 307
IS  - 13
N2  - 
To the Editor: In the study by Dr Kostis and colleagues,1 the main outcome measures were cardiovascular death and all-cause mortality. After 22 years, approximately 60% of participants from the Systolic Hypertension in the Elderly Program (SHEP) trial died, and less than 50% of the deaths were from a cardiovascular cause. There were no statistically significant differences in all-cause mortality by the various techniques the investigators used in analyzing these data (area between active and placebo survival curves, log-rank test, time to 70th percentile survival). Instead, there were statistically significant differences between the intervention and control groups only for the outcome of cardiovascular death.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.389
UR  - http://dx.doi.org/10.1001/jama.2012.389
ER  -